Second phase 2/3 placebo-controlled trial of PBI-4050 in Idiopathic Pulmonary Fibrosis patients who have failed to tolerate nintedanib or pirfenidone.

Trial Profile

Second phase 2/3 placebo-controlled trial of PBI-4050 in Idiopathic Pulmonary Fibrosis patients who have failed to tolerate nintedanib or pirfenidone.

Planning
Phase of Trial: Phase II/III

Latest Information Update: 10 May 2017

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Pulmonary fibrosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 May 2017 According to a ProMetic Life Sciences media release, the company scheduled to initiate this trial in second quarter of 2017.
    • 20 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top